Showing 1461-1470 of 1697 results for "".
- Application Submitted to Begin Clinical Development of an Oral Therapy for Agitation in Alzheimer’shttps://practicalneurology.com/news/application-submitted-to-begin-clinical-development-of-an-oral-therapy-for-agitation-in-alzheimers/2485311/Mandara Biopharma (Boulder, CO) has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to initiate clinical development of an oral dronabinol formulation for the treatment of agitation associated with Alzheimer disease (AD). The investigational
- Small Molecule Kinase Inhibitor Slowed Clinical Progression in People with Dementia with Lewy Bodieshttps://practicalneurology.com/news/small-molecule-kinase-inhibitor-associated-with-progression-in-people-with-dementia-with-lewy-bodies/2484935/Treatment with neflamapimod (CervoMed, Boston, MA) —an investigational, orally administered small molecule kinase inhibitor—was associated with significant improvements in clinical and biomarker outcomes in people with dementia with Lewy bodies (DLB), according to findings from the extension-phas
- New Guidelines Issued for Gene Therapy Treatment in Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/new-guidelines-issued-for-gene-therapy-treatment-in-duchenne-muscular-dystrophy/2483121/The Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) have jointly published consensus guidelines on the safe and equitable administration of gene therapy for Duchenne muscular dystrophy (DMD) in Neuromuscular Disorders. The recommendations provide neurolo
- AAIC Award Recipients Recognized at 2025 Meetinghttps://practicalneurology.com/news/aaic-award-recipients-recognized-at-2025-meeting/2475887/At the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), the organization recognized several award recipients for their contributions to the field across research, neuroimaging, mentorship, leadership, and philanthropy. The organization presented 3 AAIC Lifetime
- Baseline CDR-GS, MMSE Scores May Predict DMT Eligibility Window for Early Alzheimer’shttps://practicalneurology.com/news/baseline-cdr-gs-mmse-scores-may-predict-dmt-eligibility-window-for-early-alzheimers/2475886/A study presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC) examined the eligibility window of disease-modifying therapies (DMTs) for the treatment of people with early Alzheimer disease (AD). An analysis of the study’s results revealed that higher Clinica
- Carotid Revascularization Superior to Medical Management in Preventing Recurrent Stroke in People with Ipsilateral Carotid Webhttps://practicalneurology.com/news/carotid-revascularization-superior-to-medical-management-in-preventing-recurrent-stroke-in-people-with-ipsilateral-carotid-web/2473950/Relative to carotid revascularization, medical management (antiplatelet or anticoagulation therapy) was associated with increased risk of recurrent ischemic stroke in patients with ischemic stroke and ipsilateral carotid web according to results of a systematic review and meta-analysis presented
- Study Identifies Significant Variations in Pediatric MOGAD Treatmenthttps://practicalneurology.com/news/study-identifies-significant-variations-in-pediatric-mogad-treatment/2473800/The results of a study presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025 found significant variations in how neurologists treat pediatric individuals with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Res
- Investigational Therapy Significantly Improved Guillain-Barré Syndrome Symptomshttps://practicalneurology.com/news/investigational-therapy-significantly-improved-guillain-barre-syndrome-symptoms/2470935/Treatment with the investigational therapy ANX005 (Annexon, Brisbane, CA) was associated with faster and greater improvements in muscle strength and disability for people with Guillain-Barré syndrome compared with standard therapies such as intravenous immunoglobulin (IVIg) or plasma excha
- Treatment with Ecopipam for Children and Adolescents with Tourette Syndrome Shows No Effect on Psychiatric Comorbiditieshttps://practicalneurology.com/news/treatment-with-ecopipam-for-children-and-adolescents-with-tourette-syndrome-not-linked-to-changes-in-measures-of-adhd-anxiety-ocd-or-depression/2470595/For children and adolescents with Tourette syndrome (TS), treatment with the D1 receptor antagonist ecopipam (Emalex Biosciences, Chicago, IL) was not associated with significant effects on common psychiatric comorbidities in the subgroups of participants with attention deficit disorder (ADHD), a
- Comorbidities Linked with Increased Disease Activity in Individuals with MShttps://practicalneurology.com/news/comorbidities-linked-with-increased-disease-activity-in-individuals-with-ms/2470579/Study results presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) demonstrated that higher comorbidity burden is associated with increased disease activity in people with multiple sclerosis (MS). This study emphasizes the importance